Infex Therapeutics raises £4.3M to fight antimicrobial resistance

What's the deal? Infex TherapeuticsDealroom has a profile for this one. Try Dealroom →, a UK-based biotech company, has raised £4.3M in funding. The company focuses on developing treatments to combat antimicrobial resistance — one of the most pressing threats in modern medicine.

The signal: Infex Therapeutics, which Dealroom classifies as an early-growth-stage company developing and licensing drugs for critical pandemic infections, is raising capital in a niche that has long struggled to attract private investment despite its outsized public health significance. The £4.3M round underscores continued, if modest, investor commitment to antimicrobial resistance at a time when regulatory incentives and pull-funding models are still being debated across the US and EU.

Read more: finsmes.com